{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:19Z","timestamp":1707525619506},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"DOI":"10.7759\/cureus.52506","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:39:25Z","timestamp":1705595965000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case Report of Drug Interactions Between Nirmatrelvir\/Ritonavir and Tacrolimus in a Patient With Systemic Lupus Erythematosus"],"prefix":"10.7759","author":[{"given":"Nanae","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/686480","article-title":"Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review","volume":"2010","author":"Yoon KH","year":"2010","unstructured":"Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol. 2010, 2010:686480. 10.1155\/2010\/686480","journal-title":"J Biomed Biotechnol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen DR","year":"2021","unstructured":"Owen DR, Allerton CM, Anderson AS, et al.. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021, 374:1586-93. 10.1126\/science.abl4784","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos NH","year":"2022","unstructured":"Loos NH, Beijnen JH, Schinkel AH. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?. Int J Mol Sci. 2022, 23:10.3390\/ijms23179866","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda S","year":"2006","unstructured":"Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006, 112:184-98. 10.1016\/j.pharmthera.2006.04.006","journal-title":"Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2023.e00322","article-title":"Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient","volume":"36","author":"Maynard RD","year":"2023","unstructured":"Maynard RD, Bates P, Korpi-Steiner N. Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient. Pract Lab Med. 2023, 36:e00322. 10.1016\/j.plabm.2023.e00322","journal-title":"Pract Lab Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (nirmatelvir\/ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report","volume":"54","author":"Prikis M","year":"2022","unstructured":"Prikis M, Cameron A. Paxlovid (nirmatelvir\/ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report. Transplant Proc. 2022, 54:1557-60. 10.1016\/j.transproceed.2022.04.015","journal-title":"Transplant Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/15563659709043372","article-title":"Tacrolimus (FK 506) overdose: a report of five cases","volume":"35","author":"Mrvos R","year":"1997","unstructured":"Mrvos R, Hodgman M, Krenzelok EP. Tacrolimus (FK 506) overdose: a report of five cases. J Toxicol Clin Toxicol. 1997, 35:395-9. 10.3109\/15563659709043372","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000072339.10649.9C","article-title":"Coadministration of tacrolimus with anti-acid drugs","volume":"76","author":"Chisholm MA","year":"2003","unstructured":"Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Coadministration of tacrolimus with anti-acid drugs. Transplantation. 2003, 76:665-6. 10.1097\/01.TP.0000072339.10649.9C","journal-title":"Transplantation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010519","article-title":"Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects","volume":"41","author":"Bekersky I","year":"2001","unstructured":"Bekersky I, Dressler D, Alak A, Boswell GW, Mekki QA. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol. 2001, 41:628-35. 10.1177\/00912700122010519","journal-title":"J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre F","year":"2023","unstructured":"Lemaitre F, Budde K, Van Gelder T, et al.. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19. Ther Drug Monit. 2023, 45:191-9. 10.1097\/FTD.0000000000001014","journal-title":"Ther Drug Monit"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf SE","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol. 2012, 73:579-87. 10.1111\/j.1365-2125.2011.04114.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2674","article-title":"Genomewide association study of simvastatin pharmacokinetics","volume":"112","author":"Mykk\u00e4nen AJ","year":"2022","unstructured":"Mykk\u00e4nen AJ, Taskinen S, Neuvonen M, et al.. Genomewide association study of simvastatin pharmacokinetics. Clin Pharmacol Ther. 2022, 112:676-86. 10.1002\/cpt.2674","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11010037","article-title":"Pharmacogenetics of direct oral anticoagulants: a systematic review","volume":"11","author":"Raymond J","year":"2021","unstructured":"Raymond J, Imbert L, Cousin T, Duflot T, Varin R, Wils J, Lamoureux F. Pharmacogenetics of direct oral anticoagulants: a systematic review. J Pers Med. 2021, 11:10.3390\/jpm11010037","journal-title":"J Pers Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/223078-a-case-report-of-drug-interactions-between-nirmatrelvirritonavir-and-tacrolimus-in-a-patient-with-systemic-lupus-erythematosus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:43Z","timestamp":1707509563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/223078-a-case-report-of-drug-interactions-between-nirmatrelvirritonavir-and-tacrolimus-in-a-patient-with-systemic-lupus-erythematosus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.52506","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}